血清半乳甘露聚糖可预测真菌性腹膜炎腹膜透析患者的不良结局
本研究评估了血清半乳甘露聚糖指数(GMI)在监测腹膜透析(PD)相关真菌性腹膜炎治疗反应中的价值。
要点
- 治疗后血清GMI水平较高或持续阳性与腹膜透析真菌性腹膜炎患者死亡风险增加相关。
- 血清GMI动态下降可反映抗真菌治疗有效。
- 基线GMI水平在死亡与存活患者间无显著差异。
核心结论
- 血清GMI是腹膜透析真菌性腹膜炎患者风险分层和治疗反应监测的优秀生物标志物。
主要发现
- 3个月死亡11例(14%),死亡与存活患者在人口学、实验室、治疗特征及基线血清GMI上无差异。
- 治疗结束后血清GMI在随访期间逐渐下降,死亡患者治疗后血清GMI水平显著更高且更可能呈阳性。
临床怎么用
- 在腹膜透析真菌性腹膜炎患者中,可动态监测血清GMI以评估治疗反应和辅助风险分层。
局限性
- 仅纳入及时拔除PD导管且有后续GMI测量的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The potential value of serum galactomannan index (GMI) in monitoring treatment response in patients with fungal peritonitis who are receiving peritoneal dialysis (PD) was assessed in the present study. METHODS: The study included all Thailand fungal PD-related infectious complications surveillance (MycoPDICS) DATA study participants who had timely PD catheter removal and availability of both baseline and ≥2 subsequent serum GMI measurements after starting antifungal therapy (if available). Serum GMI was assessed by direct double-sandwich enzyme-linked immunosorbent assay with reference to positive and negative control samples. Comparisons of categorical variables among groups were analyzed by Fisher's exact test for categorical data and the Wilcoxon rank-sum test for continuous variables. Mortality outcomes were analyzed by survival analyses using Kaplan-Meier curves with Log-rank test. RESULTS: Seventy-six (46%) of 166 participants from 21 PD centers between 2018 and 2022 were included. The median age was 58 (50-65) years, and a half of the patients (50%) had type II diabetes. Nineteen (25%) and 57 (75%) episodes were caused by yeast and mold, respectively. Death occurred in 11 (14%) patients at 3 months, and no differences were observed in demographics, laboratories, treatment characteristics, or in baseline serum GMI between those who died and those who survived. Serum GMI progressively declined over the follow-up period after the completion of treatment. Patients who died had significantly higher posttreatment serum GMI levels and were more likely to have positive GMI after treatment. CONCLUSION: Serum GMI is an excellent biomarker for risk stratification and treatment response monitoring in patients on PD with fungal peritonitis.
引用
- Kanjanabuch T, Nopsopon T, Saejew T, et al. Serum Galactomannan: A Predictor of Poor Outcomes in Peritoneal Dialysis Patients With Fungal Peritonitis. Kidney Int Rep. 2023. PMID: 38344722. doi:10.1016/j.ekir.2023.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。